Savara (SVRA) Operating Income (2010 - 2026)
Savara (SVRA) posted quarterly Operating Income of -$39.0 million for Q1 2026, down 37.12% year-over-year from -$62.0 million in Q1 2025, and down 16.67% quarter-over-quarter from -$33.4 million in Q4 2025.
Analysis
Savara (SVRA) Operating Income (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Operating Income for 17 consecutive years, with -$39.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 37.12% year-over-year to -$39.0 million; the TTM figure through Mar 2026 stood at -$134.1 million (down 22.86% YoY), while the FY2025 annual figure was -$123.5 million, down 19.72% from the prior year.
- Operating Income eased to -$39.0 million in Q1 2026 per SVRA's latest filing, from -$33.4 million in the prior quarter.
- Across five years, Operating Income topped out at -$8.0 million in Q1 2022 and bottomed at -$39.0 million in Q1 2026.
- Historically, Operating Income has averaged -$21.4 million across 5 years, with a median of -$22.5 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Income gained 22.74% — and 2024, when it plunged 89.76%.
- Savara's Operating Income stood at -$10.9 million in 2022, then sank by 62.11% to -$17.6 million in 2023, then plunged by 76.82% to -$31.2 million in 2024, then dropped by 7.2% to -$33.4 million in 2025, then dropped by 16.67% to -$39.0 million in 2026.
- Business Quant data shows SVRA's Operating Income at -$39.0 million in Q1 2026, -$33.4 million in Q4 2025, and -$30.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | -40.97 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -40.97 Mn |
| Mar 31, 2026 | -38.99 Mn |
| Dec 31, 2025 | -33.42 Mn |
| Sep 30, 2025 | -30.26 Mn |
| Jun 30, 2025 | -31.44 Mn |
| Mar 31, 2025 | -28.44 Mn |
| Dec 31, 2024 | -31.17 Mn |
| Sep 30, 2024 | -26.36 Mn |
| Jun 30, 2024 | -23.19 Mn |
| Mar 31, 2024 | -22.48 Mn |
| Dec 31, 2023 | -17.63 Mn |
| Sep 30, 2023 | -18.04 Mn |
| Jun 30, 2023 | -12.22 Mn |
| Mar 31, 2023 | -12.11 Mn |
| Dec 31, 2022 | -10.88 Mn |
| Sep 30, 2022 | -10.54 Mn |
| Jun 30, 2022 | -9.38 Mn |
| Mar 31, 2022 | -8.05 Mn |
| Dec 31, 2021 | -10.64 Mn |
| Sep 30, 2021 | -9.97 Mn |